Dendrosome-based delivery of siRNA against E6 and E7 oncogenes in cervical cancer

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 6, Issue 3, 2010, Pages 463-470

  Dutta, Tathagata ^a   Burgess, Melinda ^a   McMillan, Nigel A J ^a   Parekh, Harendra S ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cervical cancer; Dendrimer; Dendrosome; E6 E7 oncogenes; siRNA delivery

Indexed keywords

CERVICAL CANCER; CERVICAL CANCER CELLS; CERVICAL CANCERS; DELIVERY VEHICLE; DENDRIMER GENERATION; DENDROSOMES; E7 ONCOGENE; ENTRAPMENT EFFICIENCY; FLUORESCEIN ISOTHIOCYANATE; GREEN FLUORESCENCE PROTEINS; IN-VITRO; IN-VIVO; SIRNA DELIVERY; SIRNA TREATMENT; SMALL INTERFERING RNA (SIRNA); TARGET GENES; TOXIC EFFECT; VESICLE SIZE;

CELLS; DENDRIMERS; DYES; FLUORESCENCE; ONCOGENIC VIRUSES; OPTIMIZATION; PROTEINS; TOXIC MATERIALS; ZETA POTENTIAL;

RNA;

DENDRIMER; DENDROSOME; DRUG CARRIER; FLUORESCEIN ISOTHIOCYANATE; GREEN FLUORESCENT PROTEIN; NITROGEN; PHOSPHATE; PROTEIN E6; PROTEIN E7; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1A; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN;

ARTICLE; CANCER CELL; COMPLEX FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG UPTAKE; GENE DELIVERY SYSTEM; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; NANOENCAPSULATION; ONCOGENE; UTERINE CERVIX CANCER; ZETA POTENTIAL; CELL DEATH; FEMALE; HELA CELL LINE; METABOLISM; PARTICLE SIZE; PATHOLOGY; UTERINE CERVIX TUMOR; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL DEATH; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DENDRIMERS; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; GENE KNOCKDOWN TECHNIQUES; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PARTICLE SIZE; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; UTERINE CERVICAL NEOPLASMS;

EID: 77952744356     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2009.12.001     Document Type: Article

References (33)

1. Franco E.L., Schlecht N.F., and Saslow D. The epidemiology of cervical cancer. Cancer 9 (2006) 348-359
2. DiPaolo J.A., and Alvarez-Salas L.M. Advances in the development of therapeutic nucleic acids against cervical cancer. Expert Opin Biol Ther 4 (2004) 1251-1264
3. Parkin D.M., Bray F.I., and Devesa S.S. Cancer burden in the year 2000, The global picture. Eur. J Cancer 37 (2001) S4-S66
4. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics. CA Cancer J Clin 55 (2002) 74-108
5. Mantovani F., and Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20 (2001) 7874-7887
6. Schniffner M., and Whitaker N.J. Human papillomavirus induced carcinogenesis and the ubiquitin-proteasome system. Semin Cancer Biol 13 (2003) 59-67
7. Lopez-Ocejo O., Viloria-Petit A., Bequet-Romero M., Mukhopadhyay D., Rak J., and Kerbel R.S. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 19 (2000) 4611-4620
8. Bequet-Romero M., and Lopez-Ocejo O. Angiogenesis modulators expression in culture cell lines positives for HPV-16 oncoproteins. Biochem. Biophys. Res. Commun 277 (2000) 55-61
9. Toussaint-Smith E., Donner D.B., and Roman A. Papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene 23 (2004) 2988-2995
10. Dasgupta R., and Perrimon N. Using RNAi to catch Drosophila genes in a web of interactions: insights into cancer research. Oncogene 23 (2004) 8359-8365
11. Jiang M., and Milner J. Selective silencing of viral gene expression in HPV positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 21 (2002) 6041-6048
12. Yoshinouchi M., Yamada T., Kizaki M., Fen J., Koseki T., and Ikeda Y. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol Ther 8 (2003) 762-768
13. Yamato K., Fen J., Kobuchi H., Nasu Y., Yamada T., Nishihara T., et al. Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA. Cancer Gene Ther 13 (2006) 234-241
14. Butz K., Ristriani T., Hengstermann A., Denk C., Scheffner M., and Hoppe- Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 22 (2003) 5938-5945
15. Hall A.H., and Alexander K.A. RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J Virol 77 (2003) 6066-6069
16. Gu W., Putral L., Hengst K., Minto K., Saunders N.A., Leggatt G., and McMillan N.A.J. Inhibition of cell growth in vitro and in vivo with lentiviral vector delivered short hairpin RNA targeting human papilloma virus E6 and E7 oncogenes. Cancer Gene Ther 13 (2006) 1023-1032
17. Aigner A. Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. J Biomed Biotechnol 2006 (2006) 1-15
18. Gilmore I.R., Fox S.P., Hollins A.J., Sohail M., and Akhtar S. The design and exogenous delivery of siRNA for post-transcriptional gene silencing. J Drug Target 12 (2004) 315-340
19. Gilmore I.R., Fox S.P., Hollins A.J., Sohail M., and Akhtar S. Delivery strategies for siRNA-mediated gene silencing. Current Drug Deliv 3 (2006) 147-155
20. Kawakami S., and Hashida M. Targeted delivery systems of small interfering RNA by systemic administration. Drug Metabol Pharmacokinet 22 (2007) 142-147
21. Akhtar S., and Benter I.F. Non viral delivery of synthetic siRNAs in vivo. J Clin Investig 117 (2007) 3623-3632
22. Tripathi P.K., Khopade A.J., Dutta T., Ummamaheshwari R.B., Jain S., Saraf D.K., and Jain N.K. Dendrimer polycations for the delivery of genes. Indian J Pharm Sci 65 (2003) 1-15
23. Dutta T., and Jain N.K. Targeting potential and anti HIV activity of mannosylated lamivudine loaded poly(propyleneimine) dendrimer. Biochim Biophys Acta 1770 (2007) 681-686
24. Dutta T., Garg M., Dubey V., Mishra D., Singh K., Pandita D., et al. Toxicological investigations on surface engineered fifth generation poly(propyleneimine) dendrimers in vivo. Nanotoxicology 2 (2008) 62-70
25. Bielinska A.V., Latalto J.F.K., and Baker J.R. The interaction of plasmid DNA with polyamidoamine dendrimers; mechanism of complex formation and analysis of alternations induced in nuclear sensitivity and transcriptional activity of the complexed DNA. Biochim Biophys Acta 1353 (1997) 180-186
26. Lechardeur D., Sohn K.J., Haardt M., Joshi P.B., Monek M., Grahm R.W., et al. Metabolic stability of plasmid DNA in the cytosol: A potential barrier to gene transfer. Gene Therapy 6 (1999) 482-489
27. Nishikawa M., and Huang L. Non-viral vectors in the new millennium. Delivery barriers in gene transfer. Human Gene Therapy 12 (2001) 861-864
28. Dutta T., Agashe H.B., Vijayarajkumar P., Joshi M., and Jain N.K. Dendrosome based gene delivery. J Exp Nanoscience 1 (2006) 235-248
29. Dutta T., Garg M., and Jain N.K. Poly (propyleneimine) dendrimer and dendrosome mediated genetic immunization against hepatitis B. Vaccine 26 (2008) 3389-3394
30. Putral L., Bywater M., Gu W., Saunders N., Gabrielli B., Leggatt G., et al. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol Pharmacol 68 (2005) 1311-1319
31. Qin L., Pahud D.R., Ding Y., Bielinska A.V., Kukowska-Lataloo J.F., Baker J.R., et al. Efficient transfer of genes into murine cardiac graft by starburst PAMAM dendrimers. Hum Gene Ther 9 (1998) 553-558
32. Kang H., DeLong R., Fisher M.H., and Juliano R.L. Tat conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm Res 22 (2005) 2099-2106
33. Gregoriadis G., Saffie R., and de Souza B. Liposome mediated DNA vaccination. FEBS Lett 402 (1997) 107-1110